Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a
pioneering alternative asset manager specializing in leveraging
longevity and actuarial technology to offer uncorrelated investment
opportunities, today announced the commencement of an underwritten
public offering of 12,500,000 shares of its common stock, including
10,000,000 shares of common stock to be sold by the Company and
2,500,000 to be sold by certain stockholders of the Company (the
“Selling Stockholders”). The Company and the Selling Stockholders
also expect to grant the underwriters a 30-day option to purchase
up to an additional 1,500,000 shares of common stock from the
Company and up to an additional 375,000 shares of common stock from
the Selling Stockholders.
Abacus intends to use net proceeds of the
primary portion of the offering for its operations, including the
purchase of life settlement policies, to support its overall
business strategy, for working capital purposes, and for general
corporate purposes, which may include funding previously announced
and future acquisitions and repayment and refinancing of its
indebtedness. Abacus will receive no proceeds from the secondary
portion of the offering.
The offering is subject to general market
conditions, and there can be no assurances as to whether or when
the offering may be completed, or as to the size or terms of the
offering.
Piper Sandler & Co., TD Securities (USA)
LLC, KKR Capital Markets LLC, B. Riley Securities, Inc. and SG
Americas Securities, LLC are acting as joint book-running managers
and representatives of the underwriters of the proposed
offering.
The registration statements on Form S-3
(including the accompanying prospectuses for each registration
statement) relating to the proposed offering have been filed with
the Securities and Exchange Commission (the “SEC”) and became
effective on November 14, 2024. Copies of the prospectus
supplements relating to the offering, when filed, may be obtained
on the SEC’s website located at https://www.sec.gov. When
available, copies of the prospectus supplements related to the
offering may also be obtained from: Piper Sandler & Co. by mail
at 1251 Avenue of the Americas, 6th Floor, New York, NY 10020 or by
email at prospectus@psc.com; TD Securities (USA) LLC by mail at 1
Vanderbilt Avenue, New York, NY 10017, by telephone at (855)
495-9846 or by email at TD.ECM_Prospectus@tdsecurities.com; KKR
Capital Markets LLC by mail at 30 Hudson Yards, 75th Floor, New
York, NY 10001, Attention: Prospectus Delivery; B. Riley
Securities, Inc. by mail at 1300 17th Street North, Suite 1300,
Arlington, VA 22209, by telephone at (703) 312-9580 or by email at
prospectuses@brileyfin.com; or SG Americas Securities, LLC by mail
at 245 Park Avenue, New York, NY 10167 or by email at
us-ny-prospectus@sgcib.com. The final terms of the offering will be
disclosed in the final prospectus supplements to be filed with the
SEC.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy the shares of the
Company’s common stock or any other securities, nor shall there be
any sale of such shares of common stock or any other securities in
any state or other jurisdiction in which such offer, solicitation
or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or other jurisdiction.
Any offers, solicitations or offers to buys, or any sales of
securities will be made in accordance with the registration
requirements of the U.S. Securities Act of 1933, as amended.
About
Abacus
Abacus is a pioneering global alternative asset
manager and market maker specializing in uncorrelated financial
products. The Company leverages its longevity data and actuarial
technology to purchase life insurance policies from consumers
seeking liquidity. This creates a high-return asset class
uncorrelated to market fluctuations for institutional
investors.
With nearly $3 billion in assets under
management, including pending acquisitions, Abacus is the only
publicly traded global alternative asset manager focused on
lifespan-based financial products.
Forward Looking Statements
All statements in this press release (and oral
statements made regarding the subjects of this press release) other
than historical facts are forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements rely on a number of
assumptions concerning future events and are subject to a number of
uncertainties and factors that could cause actual results to differ
materially from such statements, many of which are outside the
control of Abacus. Forward-looking information includes but is not
limited to statements regarding the proposed offering, including
the expected closing of the proposed offering; Abacus’s financial
and operational outlook; Abacus’s operational and financial
strategies, including planned growth initiatives and the benefits
thereof, Abacus’s ability to successfully effect those strategies,
and the expected results therefrom. These forward-looking
statements generally are identified by the words “believe,”
“project,” “estimate,” “expect,” ”intend,” “anticipate,” “goals,”
“prospects,” “will,” “would,” “will continue,” “will likely
result,” and similar expressions (including the negative versions
of such words or expressions).
While Abacus believes that the assumptions
concerning future events are reasonable, it cautions that there are
inherent difficulties in predicting certain important factors that
could impact the future performance or results of its business. The
factors that could cause results to differ materially from those
indicated by such forward-looking statements include, but are not
limited to: the fact that Abacus’s loss reserves are bases on
estimates and may be inadequate to cover its actual losses; the
failure to properly price Abacus’s insurance policies; the
geographic concentration of Abacus’s business; the cyclical nature
of Abacus’s industry; the impact of regulation on Abacus’s
business; the effects of competition on Abacus’s business; the
failure of Abacus’s relationships with independent agencies; the
failure to meet Abacus’s investment objectives; the inability to
raise capital on favorable terms or at all; the effects of acts of
terrorism; and the effectiveness of Abacus’s control environment,
including the identification of control deficiencies.
These forward-looking statements are also
affected by the risk factors, forward-looking statements and
challenges and uncertainties set forth in documents filed by Abacus
with the SEC from time to time, including the Annual Report on
Form 10-K, as amended, and Quarterly Reports on Form 10-Q and
subsequent periodic reports. These filings identify and address
other important risks and uncertainties that could cause actual
events and results to differ materially from those contained in the
forward-looking statements. Abacus cautions you not to place undue
reliance on the forward-looking statements contained in this press
release. Forward-looking statements speak only as of the date they
are made. Readers are cautioned not to put undue reliance on
forward-looking statements, and Abacus assumes no obligation and,
except as required by law, does not intend to update or revise
these forward-looking statements, whether as a result of new
information, future events, or otherwise. Abacus does not give any
assurance that it will achieve its expectations.
Contacts:
Robert Phillips – SVP Investor
Relationsrob@abacuslife.com(321) 290-1198
David Jackson – IR/Capital Markets
Associatedjackson@abacuslife.com(321) 299-0716
Abacus Life Public
Relationspress@abacuslife.com
Abacus Life (NASDAQ:ABLLW)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Abacus Life (NASDAQ:ABLLW)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025